Core Insights - Abbott Laboratories reported third-quarter earnings that exceeded analyst expectations, leading to a 1.5% increase in its stock price, outperforming the S&P 500 index's 0.5% gain [1] Financial Performance - Abbott's revenue for the quarter was approximately 10.64billion,reflectingayear−over−yeargrowthofnearly52.12 billion, equating to 1.21pershare,slightlyabovetheconsensusestimatesof10.56 billion in revenue and 1.20pershare[2]−Themedicaldevicessegmentwastheprimarydriverofgrowth,generatingnearly4.75 billion, a 14% increase compared to the previous year [2] - The nutrition segment also performed well, with a 10% increase to almost 2.1billion[2]ManagementGuidance−CEORobertFordexpressedconfidenceinthecompany′sperformance,indicatingthatAbbottiswell−positionedtoachievetheupperendofitsinitialguidancefortheyear[3]−Thecompanyraiseditsadjustedearningsguidanceforfull−year2024toarangeof4.64 to $4.70 per share, anticipating revenue growth of 9.5% to 10% over 2023 results [3]